These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 36108528)

  • 1. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.
    Tang W; Sun G; Ji GW; Feng T; Zhang Q; Cao H; Wu W; Zhang X; Liu C; Liu H; Huang T; Liu L; Xia Y; Wang X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung cancer via the transformation of M2 into M1 macrophages by ferroptosis by NRF2/HO-1.
    Mei L; Long J; Wu S; Mei M; Mei D; Qiu H
    Anticancer Drugs; 2024 Apr; 35(4):333-343. PubMed ID: 38241194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.
    Yu Y; Nie G; Ren YW; Ouyang L; Ni CM
    Cell Cycle; 2024 Mar; 23(6):682-692. PubMed ID: 38794797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8
    Zhu CX; Yan K; Chen L; Huang RR; Bian ZH; Wei HR; Gu XM; Zhao YY; Liu MC; Suo CX; Li ZK; Yang ZY; Lu MQ; Hua XF; Li L; Zhao ZB; Sun LC; Zhang HF; Gao P; Lian ZX
    J Hepatol; 2024 Oct; 81(4):690-703. PubMed ID: 38759889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
    J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.
    Tang B; Zhu J; Li J; Fan K; Gao Y; Cheng S; Kong C; Zheng L; Wu F; Weng Q; Lu C; Ji J
    Cell Commun Signal; 2020 Oct; 18(1):174. PubMed ID: 33115468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
    Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
    Front Immunol; 2019; 10():1643. PubMed ID: 31379842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion.
    Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L
    Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
    Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
    Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
    Small; 2024 Aug; 20(31):e2311702. PubMed ID: 38456371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab induces ferroptosis and enhances CD8
    Hou CY; Lv P; Yuan HF; Zhao LN; Wang YF; Zhang HH; Yang G; Zhang XD
    Acta Pharmacol Sin; 2024 Sep; 45(9):1951-1963. PubMed ID: 38760543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.